Literature DB >> 23922014

Engineering of bacteria for the visualization of targeted delivery of a cytolytic anticancer agent.

Sheng-Nan Jiang1, Seung-Hwan Park, Hee Jung Lee, Jin Hai Zheng, Hyung-Seok Kim, Hee-Seung Bom, Yeongjin Hong, Michael Szardenings, Myung Geun Shin, Sun-Chang Kim, Vasilis Ntziachristos, Hyon E Choy, Jung-Joon Min.   

Abstract

A number of recent reports have demonstrated that attenuated Salmonella typhimurium are capable of targeting both primary and metastatic tumors. The use of bacteria as a vehicle for the delivery of anticancer drugs requires a mechanism that precisely regulates and visualizes gene expression to ensure the appropriate timing and location of drug production. To integrate these functions into bacteria, we used a repressor-regulated tetracycline efflux system, in which the expression of a therapeutic gene and an imaging reporter gene were controlled by divergent promoters (tetAP and tetRP) in response to extracellular tetracycline. Attenuated S. typhimurium was transformed with the expression plasmids encoding cytolysin A, a therapeutic gene, and renilla luciferase variant 8, an imaging reporter gene, and administered intravenously to tumor-bearing mice. The engineered Salmonella successfully localized to tumor tissue and gene expression was dependent on the concentration of inducer, indicating the feasibility of peripheral control of bacterial gene expression. The bioluminescence signal permitted the localization of gene expression from the bacteria. The engineered bacteria significantly suppressed both primary and metastatic tumors and prolonged survival in mice. Therefore, engineered bacteria that carry a therapeutic and an imaging reporter gene for targeted anticancer therapy can be designed as a theranostic agent.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23922014      PMCID: PMC3831040          DOI: 10.1038/mt.2013.183

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  49 in total

Review 1.  Biological gene delivery vehicles: beyond viral vectors.

Authors:  Yiqi Seow; Matthew J Wood
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

2.  Improved mycobacterial tetracycline inducible vectors.

Authors:  Kerstin J Williams; Graham Joyce; Brian D Robertson
Journal:  Plasmid       Date:  2010-04-29       Impact factor: 3.466

3.  Combination bacteriolytic therapy for the treatment of experimental tumors.

Authors:  L H Dang; C Bettegowda; D L Huso; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

4.  Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer.

Authors:  Vu H Nguyen; Hyung-Seok Kim; Jung-Min Ha; Yeongjin Hong; Hyon E Choy; Jung-Joon Min
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

5.  Drug-inducible remote control of gene expression by probiotic Escherichia coli Nissle 1917 in intestine, tumor and gall bladder of mice.

Authors:  Holger Loessner; Sara Leschner; Anne Endmann; Kathrin Westphal; Kathrin Wolf; Katja Kochruebe; Tewfik Miloud; Josef Altenbuchner; Siegfried Weiss
Journal:  Microbes Infect       Date:  2009-08-07       Impact factor: 2.700

6.  Insertion or deletion of the Cheo box modifies radiation inducibility of Clostridium promoters.

Authors:  S Nuyts; L Van Mellaert; S Barbé; E Lammertyn; J Theys; W Landuyt; E Bosmans; P Lambin; J Anné
Journal:  Appl Environ Microbiol       Date:  2001-10       Impact factor: 4.792

7.  Spatial-temporal imaging of bacterial infection and antibiotic response in intact animals.

Authors:  M Zhao; M Yang; E Baranov; X Wang; S Penman; A R Moossa; R M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

Review 8.  Engineering the perfect (bacterial) cancer therapy.

Authors:  Neil S Forbes
Journal:  Nat Rev Cancer       Date:  2010-10-14       Impact factor: 60.716

9.  Inhibition of tumor growth and metastasis by a combination of Escherichia coli-mediated cytolytic therapy and radiotherapy.

Authors:  Sheng-Nan Jiang; Thuy X Phan; Taek-Keun Nam; Vu H Nguyen; Hyung-Seok Kim; Hee-Seung Bom; Hyon E Choy; Yeongjin Hong; Jung-Joon Min
Journal:  Mol Ther       Date:  2010-01-05       Impact factor: 11.454

10.  Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium.

Authors:  Katsuhiro Hayashi; Ming Zhao; Kensuke Yamauchi; Norio Yamamoto; Hiroyuki Tsuchiya; Katsuro Tomita; Robert M Hoffman
Journal:  J Cell Biochem       Date:  2009-04-15       Impact factor: 4.429

View more
  28 in total

Review 1.  Tumour-targeting bacteria engineered to fight cancer.

Authors:  Shibin Zhou; Claudia Gravekamp; David Bermudes; Ke Liu
Journal:  Nat Rev Cancer       Date:  2018-12       Impact factor: 60.716

Review 2.  Salmonella-Mediated Cancer Therapy: Roles and Potential.

Authors:  Vu Hong Nguyen; Jung-Joon Min
Journal:  Nucl Med Mol Imaging       Date:  2016-06-01

3.  Targeting of pancreatic cancer cells and stromal cells using engineered oncolytic Salmonella typhimurium.

Authors:  Wenzhi Tan; Mai Thi-Quynh Duong; Chaohui Zuo; Yeshan Qin; Ying Zhang; Yanxia Guo; Yeongjin Hong; Jin Hai Zheng; Jung-Joon Min
Journal:  Mol Ther       Date:  2021-08-14       Impact factor: 11.454

4.  Comparison of Anticancer Activities and Biosafety Between Salmonella enterica Serovar Typhimurium ΔppGpp and VNP20009 in a Murine Cancer Model.

Authors:  Xiaoqing Liu; Yanxia Guo; Yujie Sun; Yu Chen; Wenzhi Tan; Jung-Joon Min; Jin Hai Zheng
Journal:  Front Microbiol       Date:  2022-06-29       Impact factor: 6.064

Review 5.  Synthetic immunosurveillance systems: nanodevices to monitor physiological events.

Authors:  Yvon L Woappi; Rahul Jangiti; Om V Singh
Journal:  Biosens Bioelectron       Date:  2014-05-10       Impact factor: 10.618

6.  Isolation and Characterization of a Monobody with a Fibronectin Domain III Scaffold That Specifically Binds EphA2.

Authors:  Seung-Hwan Park; Sukho Park; Dong-Yeon Kim; Ayoung Pyo; Richard H Kimura; Ataya Sathirachinda; Hyon E Choy; Jung-Joon Min; Sanjiv Sam Gambhir; Yeongjin Hong
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

7.  Anti-tumoral effect of the mitochondrial target domain of Noxa delivered by an engineered Salmonella typhimurium.

Authors:  Jae-Ho Jeong; Kwangsoo Kim; Daejin Lim; Kwangjoon Jeong; Yeongjin Hong; Vu H Nguyen; Tae-Hyoung Kim; Sangryeol Ryu; Jeong-A Lim; Jae Il Kim; Geun-Joong Kim; Sun Chang Kim; Jung-Joon Min; Hyon E Choy
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

Review 8.  Colorectal cancer treatment using bacteria: focus on molecular mechanisms.

Authors:  Sara Ebrahimzadeh; Hossein Ahangari; Alireza Soleimanian; Kamran Hosseini; Vida Ebrahimi; Tohid Ghasemnejad; Saiedeh Razi Soofiyani; Vahideh Tarhriz; Shirin Eyvazi
Journal:  BMC Microbiol       Date:  2021-07-19       Impact factor: 3.605

9.  The engineered Salmonella typhimurium inhibits tumorigenesis in advanced glioma.

Authors:  Jian-Qiang Chen; Yue-Fu Zhan; Wei Wang; Sheng-Nan Jiang; Xiang-Ying Li
Journal:  Onco Targets Ther       Date:  2015-09-15       Impact factor: 4.147

10.  New paradigm for tumor theranostic methodology using bacteria-based microrobot.

Authors:  Sung Jun Park; Seung-Hwan Park; Sunghoon Cho; Deok-Mi Kim; Yeonkyung Lee; Seong Young Ko; Yeongjin Hong; Hyon E Choy; Jung-Joon Min; Jong-Oh Park; Sukho Park
Journal:  Sci Rep       Date:  2013-12-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.